Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Monograph System Needs Transparency, Communication – PCPC

This article was originally published in The Tan Sheet

Executive Summary

While FDA’s OTC drug monograph system is an “appropriate and rational framework” for regulating cosmetic-drug products, greater transparency and more regular communication with industry are needed, according to Personal Care Products Council executive Elizabeth Anderson.

Advertisement

Related Content

“No End In Sight” For Completing OTC Monographs – CDER Director Woodcock
Consent Decree Orders FDA Action On Triclosan OTC Monographs
EWG Supports Nano-Engineered Mineral Sunscreens In 2013 Report
Cold Indication For Antihistamines Targeted In Regulatory Agenda

Topics

Advertisement
UsernamePublicRestriction

Register

PS106834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel